Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer.
Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer.
复制标题
治疗诊断放射性核素用于肝癌经动脉放射栓塞的诊断性能
DOI：
10.3389/fonc.2020.551622
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Zuo C
中科院分区：
文献类型：
--
作者：
Li R;Li D;Jia G;Li X;Sun G;Zuo C
Primary liver tumor with hepatocellular carcinoma accounting for 75–80% of all such tumors, is one of the global leading causes of cancer-related death, especially in cirrhotic patients. Liver tumors are highly hypervascularized via the hepatic artery, while normal liver tissues are mainly supplied by the portal vein; consequently, intra-arterially delivered treatment, which includes transarterial chemoembolization (TACE) and transarterial radioembolization (TARE), is deemed as a palliative treatment. With the development of nuclear technology and radiochemistry, TARE has become an alternative for patients with hepatic cancer, especially for patients who failed other therapies, or for patients who need tumor downstaging treatment. In practice, some radionuclides have suitable physicochemical characteristics to act as radioactive embolism agents. Among them, 90Y emits β rays only and is suitable for bremsstrahlung single photon emission computed tomography (BS SPECT) and positron emission tomography (PET); meanwhile, some others, such as 131I, 153Sm, 166Ho, 177Lu, 186Re, and 188Re, emit both β and γ rays, enabling embolism beads to play a role in both therapy and single photon emission computed tomography (SPECT) imaging. During TARE, concomitant imaging provide additive diagnostic information and help to guide the course of liver cancer treatment. Therefore, we review the theranostic radionuclides that have been used or could potentially be used in TARE for liver cancer and focus on the clinical benefits of diagnostic applications, including real-time monitoring of embolism beads, evaluating irradiation dose, predicting therapy effects, and corresponding adjustments to TARE.
登录
查看更多内容
影响因子：
3.7
作者：
Hashikin NA;Yeong CH;Abdullah BJ;Ng KH;Chung LY;Dahalan R;Perkins AC
通讯作者：
Perkins AC
影响因子：
2.1
作者：
Potrebko PS;Shridhar R;Biagioli MC;Sensakovic WF;Andl G;Poleszczuk J;Fox TH
通讯作者：
Fox TH
DOI：
10.1007/s00259-011-1940-8
发表时间：
2012-02-01
影响因子：
9.1
作者：
Ahmadzadehfar, Hojjat;Muckle, Marianne;Ezziddin, Samer
通讯作者：
Ezziddin, Samer
影响因子：
10.6
作者：
Camacho, Juan C.;Kokabi, Nima;Kim, Hyun S.
通讯作者：
Kim, Hyun S.
PET和BREMSSTRAHLUNG SPECT的定量比较，用于成像肝放射栓塞后体内YTTrium-90微球分布。
影响因子：
3.7
作者：
Elschot M;Vermolen BJ;Lam MG;de Keizer B;van den Bosch MA;de Jong HW
通讯作者：
de Jong HW